Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Nanobiotix strengthens US team

Monday, October 3, 2016 23:57
% of readers think this story is Fact. Add your two cents.

Late clinical-stage cancer therapy group Nanobiotix (EPA:NANO) has strengthened its US leadership team.

The group has appointed Dr Mihail Obrocea as the head of US clinical development and Noёl Kurdi as the director of investor relations.

Obrocea joins Nanobiotix from US-based SFJ Pharmaceuticals Group, where he held the role of vice president of Clinical & Medical Affairs.

Kurdi joins Nanobiotix from the Trout Group & Trout Capital. She served as a senior associate, providing strategic investor relations counsel to biotech companies seeking access to the US and international capital markets.

“These high level profiles will contribute to reinforce Nanobiotix’s presence in the US by strengthening its clinical development and by leveraging US investors potential to continue the growth of the company,” said the statement late Monday.

Nanobiotix has successfully filed its Investigational New Drug application in the US for its prostate cancer drug NBTXR3 and plans to initiate a Phase I/II trial in three US-based oncology sites.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.